Diosynth to work with Talecris for production of recombinant Plasminogen
Diosynth Biotechnology, a division of Organon that supplies contract manufacturing services for the global biotechnology industry, has signed an agreement with Talecris Biotherapeutics for process development activities and cGMP production of clinical trial material for a unique form of recombinant Plasminogen.
Diosynth Biotechnology, a division of Organon that supplies contract manufacturing services for the global biotechnology industry, has signed an agreement with Talecris Biotherapeutics for process development activities and cGMP production of clinical trial material for a unique form of recombinant Plasminogen.
Recombinant Plasminogen is an intermediate material used in the manufacture of recombinant Plasmin, a second-generation therapy being developed by Talecris for both ophthalmic and thrombolytic indications.